• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Theravance

edit

Theravance, Inc. (Theravance) is a biopharmaceutical company with a pipeline of internally discovered product candidates. As of December 31, 2009, the Company is focused on the discovery, development and commercialization of small molecule medicines across a number of therapeutic areas, including respiratory disease, bacterial infections and gastrointestinal motility dysfunction. Its programs include VIBATIV (telavancin) with Astellas Pharma Inc. (Astellas) and its RELOVAI program (formerly referred to as Horizon) and the Bifunctional Muscarinic Antagonist-beta2 Agonist (MABA) program with GlaxoSmithKline plc (GSK).

Milestones

edit

• 
  Theravance added Michael W. Aguiar as Senior Vice President and CFO.
  Posted 11/29/10 at 8:04pm
• 
  Theravance added Rick E Winningham as Chairman and CEO.
  Posted 11/29/10 at 8:04pm
• 
  Went public with stock symbol NASDAQ:THRX.
  Posted 11/29/10 at 8:05pm
• 
  Theravance received $129M in Venture Round funding. (11/29/10)
  Posted 11/29/10 at 8:04pm via shareholder.com

Videos

Screenshots

edit

Stock Price

Sources

1. GlaxoSmithKline to Increase Its Shareholding in Theravance (files.shareholder.com) [edit]